HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
COVID-19 Drug Development
COVID-19 drug development is a research process to discover a preventative and therapeutic prescription of drugs that would control the severity of coronavirus disease. From 2020 to 2021, various drug companies, biotechnology firms, university research groups, and health organizations were started developing over 600 potential therapies for corona virus disease with various stages of preclinical or clinical research, with 391 therapeutic candidates in clinical trials, as of January 2021.
Submit your abstract Today
Title : Interdependent antioxidant therapy in covid-19 and other critical diseases
Richard Z. Cheng, Cheng Integrative Health Center, United States
Title : Biotechnological exploration of phyto-drugs against MDR bacteria targeting DNA topoisomerase I and RNA polymerase
Asit Kumar Chakraborty, Vidyasagar University, India
Title : New excipient to formulate poorly soluble APIs
Rajendran Arunagiri, Eastman, United States
Title : Limiting factors in implementing pharmacovigilance principles in the elderly
Hana Hassan, University of Bristol, United Kingdom
Title : Intellection of molecular drug delivery models -an ayurvedic perspective
Ashtavaidyan Dr. E.T. Krishnan Mooss, Vaidyaratnam Group , India
Title : Evaluation of the wound healing activity of Hyoscyamus nigar seed powder on the wistar albino rats
Jeevanath Ruban, Trincomalee Campus, Sri Lanka
Title : Comparison of dexmedetomidine and propofol with ketofol in sedation of candidates for cataract surgery
Alireza Kamali, Arak University of Medical Sciences, Iran (Islamic Republic of)
Title : Multi-detection of pharmaceutical contamination in environment
Andreia Freitas, INIAV and REQUIMTE, Portugal
Title : Exosome-like nanoparticles from plants: Promising pharmaceutical preparations and delivery carriers
Chongzhi Liu, The First Affiliated Hospital of Chengdu Medical College, China